Anders Liljeblad CEO

Roles

31.08.202631.08.2026

Transactions (including via associated entities)

DateIssuerNatureVolumePriceValueSource
31.08.2026Prostatype Genomics AB Stockholm
Other / unclassified
via Liljeblad & Co Aktiebolag
2,875,000
No cash value
2,875,000 units
31.08.2026Prostatype Genomics AB Stockholm
Other / unclassified
via Liljeblad & Co Aktiebolag
1,437,500
No cash value
1,437,500 units
31.08.2026Prostatype Genomics AB Stockholm
Bought — open marketAcquisition
via Liljeblad & Co Aktiebolag
5,750,000SEK 0.10
SEK 575,000.00